35.13
price down icon0.68%   -0.24
after-market Handel nachbörslich: 35.13
loading
Schlusskurs vom Vortag:
$35.37
Offen:
$34.35
24-Stunden-Volumen:
631.66K
Relative Volume:
0.80
Marktkapitalisierung:
$3.18B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-5.4297
EPS:
-6.47
Netto-Cashflow:
$-439.53M
1W Leistung:
-9.67%
1M Leistung:
-14.86%
6M Leistung:
-34.53%
1J Leistung:
-25.38%
1-Tages-Spanne:
Value
$34.28
$35.47
1-Wochen-Bereich:
Value
$33.53
$38.76
52-Wochen-Spanne:
Value
$33.53
$60.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name
Firmenname
Ultragenyx Pharmaceutical Inc
Name
Telefon
415-483-8800
Name
Adresse
60 LEVERONI COURT, NOVATO, CA
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
RARE's Discussions on Twitter

Vergleichen Sie RARE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RARE
Ultragenyx Pharmaceutical Inc
35.13 3.18B 522.75M -558.99M -439.53M -6.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-06-06 Hochstufung Goldman Neutral → Buy
2024-04-22 Eingeleitet RBC Capital Mkts Outperform
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-06-14 Fortgesetzt Credit Suisse Outperform
2023-06-06 Hochstufung Evercore ISI In-line → Outperform
2023-04-26 Eingeleitet Cantor Fitzgerald Overweight
2023-01-18 Fortgesetzt Canaccord Genuity Buy
2022-12-30 Fortgesetzt H.C. Wainwright Buy
2022-11-03 Hochstufung Robert W. Baird Neutral → Outperform
2022-10-13 Hochstufung Guggenheim Neutral → Buy
2022-08-01 Herabstufung Evercore ISI Outperform → In-line
2022-03-16 Hochstufung Credit Suisse Neutral → Outperform
2022-02-11 Hochstufung JP Morgan Neutral → Overweight
2021-09-30 Eingeleitet H.C. Wainwright Buy
2021-08-19 Eingeleitet UBS Sell
2021-07-15 Eingeleitet Guggenheim Neutral
2021-06-29 Hochstufung BofA Securities Neutral → Buy
2021-06-04 Fortgesetzt Robert W. Baird Neutral
2021-05-06 Hochstufung Citigroup Neutral → Buy
2021-05-06 Hochstufung Evercore ISI In-line → Outperform
2021-04-26 Fortgesetzt Credit Suisse Neutral
2021-03-02 Fortgesetzt Stifel Buy
2021-02-12 Herabstufung JP Morgan Overweight → Neutral
2020-12-07 Herabstufung Wedbush Outperform → Neutral
2020-11-24 Fortgesetzt Evercore ISI In-line
2020-11-12 Herabstufung BofA Securities Buy → Neutral
2019-08-02 Fortgesetzt Wedbush Outperform
2019-03-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-02-22 Fortgesetzt Raymond James Outperform
2019-01-02 Herabstufung Raymond James Outperform → Mkt Perform
2018-11-08 Hochstufung Citigroup Sell → Neutral
2018-09-10 Eingeleitet Morgan Stanley Equal-Weight
2018-06-21 Herabstufung Credit Suisse Outperform → Neutral
2018-05-11 Hochstufung Barclays Equal Weight → Overweight
2018-05-10 Eingeleitet Goldman Neutral
2018-04-18 Hochstufung SunTrust Hold → Buy
2018-03-22 Fortgesetzt Piper Jaffray Overweight
2018-02-21 Bestätigt Stifel Buy
2018-01-22 Hochstufung Evercore ISI In-line → Outperform
2018-01-18 Eingeleitet Credit Suisse Outperform
2017-12-05 Bestätigt Barclays Equal Weight
2017-12-04 Hochstufung Jefferies Hold → Buy
2017-09-14 Hochstufung Wedbush Neutral → Outperform
Alle ansehen

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

pulisher
Apr 02, 2025

How another firm's FDA approval could mean a big win for Denali Therapeutics - The Business Journals

Apr 02, 2025
pulisher
Apr 02, 2025

Winners and wishers: 9 potential Bay Area drug approvals coming this year - The Business Journals

Apr 02, 2025
pulisher
Apr 02, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week LowShould You Sell? - MarketBeat

Apr 02, 2025
pulisher
Mar 30, 2025

11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey

Mar 30, 2025
pulisher
Mar 29, 2025

Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey

Mar 29, 2025
pulisher
Mar 27, 2025

Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Ultragenyx price target raised to $117 from $104 at JPMorgan - TipRanks

Mar 27, 2025
pulisher
Mar 26, 2025

Ultragenyx stock hits 52-week low at $36.99 amid market challenges - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Ultragenyx stock hits 52-week low at $36.99 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 24, 2025

Ultragenyx CEO Emil Kakkis: ‘Our Future Is In Our Hands’ - insights.citeline.com

Mar 24, 2025
pulisher
Mar 24, 2025

Can UX111 Script History As The First FDA-Approved Treatment For Sanfilippo Syndrome Type A? - RTTNews

Mar 24, 2025
pulisher
Mar 19, 2025

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Ultragenyx Strengthens Team with Strategic RSU Grants Worth Millions - StockTitan

Mar 19, 2025
pulisher
Mar 18, 2025

Ultragenyx price target lowered to $115 from $140 at Piper Sandler - Yahoo Finance

Mar 18, 2025
pulisher
Mar 17, 2025

Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace

Mar 17, 2025
pulisher
Mar 12, 2025

Trending Report on X-linked Hypophosphatemia Market 2025-2032 - openPR

Mar 12, 2025
pulisher
Mar 11, 2025

Have Insiders Sold Ultragenyx Pharmaceutical Shares Recently? - Simply Wall St

Mar 11, 2025
pulisher
Mar 10, 2025

Ultragenyx pharmaceutical CFO sells $72,114 in common stock By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Ultragenyx pharmaceutical CFO sells $72,114 in common stock - Investing.com India

Mar 10, 2025
pulisher
Mar 07, 2025

Ultragenyx Pharmaceutical, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Growth Potential and Robust Pipeline - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

FDA grants priority review to gene therapy for Sanfilippo type A - Sanfilippo News

Mar 06, 2025
pulisher
Mar 05, 2025

Ultragenyx Pharmaceutical Inc Reports Q4 2024 Revenue of $165 Mi - GuruFocus.com

Mar 05, 2025
pulisher
Mar 05, 2025

Ultragenyx pharmaceutical CBO Kassberg sells $253k in stock By Investing.com - Investing.com Australia

Mar 05, 2025
pulisher
Mar 05, 2025

Ultragenyx’s chief accounting officer sells $40,710 in stock By Investing.com - Investing.com Australia

Mar 05, 2025
pulisher
Mar 05, 2025

Ultragenyx pharmaceutical executive sells $607,881 in stock By Investing.com - Investing.com Australia

Mar 05, 2025
pulisher
Mar 04, 2025

Ultragenyx pharmaceutical CBO Kassberg sells $253k in stock - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx EVP Eric Crombez sells $376,584 in stock - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx EVP Eric Crombez sells $376,584 in stock By Investing.com - Investing.com Australia

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx pharmaceutical EVP sells $635,836 in stock - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx pharmaceutical EVP sells $635,836 in stock By Investing.com - Investing.com Canada

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx pharmaceutical executive sells $607,881 in stock - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx CEO Emil Kakkis sells $4.15 million in stock By Investing.com - Investing.com UK

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx’s chief accounting officer sells $40,710 in stock - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx EVP Karah Parschauer sells $128,223 in stock By Investing.com - Investing.com Canada

Mar 04, 2025
pulisher
Mar 03, 2025

Ultragenyx Loses Bid To Toss Suit Over Henrietta Lacks' Cells - Law360

Mar 03, 2025
pulisher
Mar 03, 2025

Ultragenyx EVP Karah Parschauer sells $128,223 in stock - Investing.com India

Mar 03, 2025
pulisher
Mar 01, 2025

(RARE) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 01, 2025
pulisher
Mar 01, 2025

Y Intercept Hong Kong Ltd Raises Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Ultragenyx Pharmaceutical’s (RARE) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World

Mar 01, 2025

Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):